TNF-α抑制剂|波马利度胺Pomalidomide(CC-4047 Actimid) 免疫调节药物|CAS 19171-19-8（50810ES）

Pomalidomide又称为CC-4047、Actimid，是一种免疫药物，结构与thalidomide类似，抑制LPS诱导的TNF- alpha释放，在人PBMC中IC50为13 nM。Pomalidomide抑制IL-2刺激的T调节细胞生长（IC50≈1μM），而且Pomalidomide可以提高人外周血T细胞中IL-2产量。与CC-5013相比，Pomalidomide显著促进IL-2、IL-5和IL-10水平，稍微促进 IFN-γ水平。另外，作用于Jurkat细胞时，Pomalidomide增强SEE和Raji细胞诱导的AP-1转录活性。与Rituximab联合作用于小鼠时，Pomalidomide显著增强Rituximab对B细胞淋巴瘤的抗癌效果。

【该产品仅用于科研实验，不能用于人体】

参考文献

[1] Muller GW, et al. Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production. Bioorg Med Chem Lett, 9(11): 1625-1630 (1999).

[2] Quach H, et al. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia. 24(1): 22-32 (2010).

[3] Zhu YX, et al. Molecular mechanism of action of the immune-modulatory drugs, thalidomide, lenalidomide and pomalidomide in multiple myeloma.Leuk Leukemia & Lymphoma. 54(4): 683-687 (2013).

[4] Galustian C, et al. The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol Immunother, 58(7): 1033-1045 (2009).

[5] Schafer PH, et al. Enhancement of Cytokine Production and AP-1 Transcriptional Activity in T Cells by Thalidomide-Related Immunomodulatory Drugs. J Pharmacol Exp Ther, 305(3): 1222-1232 (2003).

[6] Hernandez-Ilizaliturri FJ, et al. Immunomodulatory Drug CC-5013 or CC-4047 and Rituximab Enhance Antitumor Activity in a Severe Combined Immunodeficient Mouse Lymphoma Model. Clin Cancer Res, 11(16): 5984-5992 (2005).

冰袋运输。粉末直接保存于-20 ºC，有效期2年。溶于DMSO。建议分装后-20ºC避光保存，避免反复冻存，至少可存放6个月。